Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...

Semaglutide has been shown to reduce the risk of complications in patients with chronic kidney disease, an indication for which it has been filed for approval, while tirzepatide has been shown to ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Semaglutide and tirzepatide prescriptions within Epic-affiliated health care systems increased slightly between 2021 and 2024, but their uptake remained limited, with only 3% of eligible patients ...

Semaglutide 2.0 mg was the most initiated medication (34.0%) vs 16.1% who initiated tirzepatide. Any use of tirzepatide jumped to 12.3% of all GLM use by December 2023, while SGLT2 inhibitor and ...

That rabbit hole includes websites that sell GLP-1 drugs “for research only,” like powdered semaglutide or tirzepatide that’s intended for use in the lab, not for humans. With just a few ...

Between 2021 and 2023, prescriptions of tirzepatide, semaglutide (Novo Nordisk), and sodium-glucose cotransporter 2 (SGLT2) inhibitors for people with T2D increased dramatically, while the use of ...

“In the future, data comparing the benefits of tirzepatide versus semaglutide for glycemic control, obesity management, and cardiovascular outcomes will help us have more informed conversations ...

Compounded drugs are custom-made and unbranded medications that contain the same active ingredient as a marketed drug, such as semaglutide or tirzepatide, pursuant to a prescription. A shortage of ...

systems in the U.S. Only 2.3% of over 39 million eligible adults received prescriptions for semaglutide or tirzepatide (Mounjaro, Zepbound) for obesity between 2021 and 2024. (JAMA) Eli Lilly is ...